Revance Therapeutics Inc [NASDAQ: RVNC] closed the trading session at $3.47.
The stocks have a year to date performance of 14.14 percent and weekly performance of 13.40 percent. The stock has been moved at 24.15 percent over the last six months. The stock has performed -16.79 percent around the most recent 30 days and changed -33.52 percent over the most recent 3-months.
If compared to the average trading volume of 2.52M shares, RVNC reached to a volume of 13014960 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Revance Therapeutics Inc [RVNC]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for RVNC shares is $4.36 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on RVNC stock is a recommendation set at 3.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Mizuho have made an estimate for Revance Therapeutics Inc shares, keeping their opinion on the stock as Neutral, with their previous recommendation back on January 29, 2024. While these analysts kept the previous recommendation, Goldman raised their target price from $30 to $8. The new note on the price target was released on January 09, 2024, representing the official price target for Revance Therapeutics Inc stock. Previously, the target price had yet another raise to $20, while Exane BNP Paribas analysts kept a Neutral rating on RVNC stock.
The Average True Range (ATR) for Revance Therapeutics Inc is set at 0.15, with the Price to Sales ratio for RVNC stock in the period of the last 12 months amounting to 1.48.
RVNC stock trade performance evaluation
Revance Therapeutics Inc [RVNC] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 13.40. With this latest performance, RVNC shares dropped by -16.79% in over the last four-week period, additionally plugging by 24.15% over the last 6 months – not to mention a drop of -60.52% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for RVNC stock in for the last two-week period is set at 53.03, with the RSI for the last a single of trading hit 68.54, and the three-weeks RSI is set at 46.55 for Revance Therapeutics Inc [RVNC]. The present Moving Average for the last 50 days of trading for this stock 3.98, while it was recorded at 3.14 for the last single week of trading, and 4.25 for the last 200 days.
Revance Therapeutics Inc [RVNC]: An insightful look at the core fundamentals
Revance Therapeutics Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 3.05 and a Current Ratio set at 4.12.
Earnings per share (EPS) analysis for Revance Therapeutics Inc [RVNC] stock
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for RVNC. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Revance Therapeutics Inc go to 11.60%.
Revance Therapeutics Inc [RVNC]: Institutional Ownership
There are presently around $82.84%, or 90.59%% of RVNC stock, in the hands of institutional investors. The top three institutional holders of RVNC stocks are: CAPITAL WORLD INVESTORS with ownership of 13.94 million shares, which is approximately 15.164%. BLACKROCK INC., holding 8.57 million shares of the stock with an approximate value of $$22.01 million in RVNC stocks shares; and BLACKROCK INC., currently with $$16.09 million in RVNC stock with ownership which is approximately 6.8092%.
